{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:59:03Z","timestamp":1784303943722,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No prior research has directly compared adverse drug event (ADE) profiles of Nivolumab and Cetuximab in head and neck cancer (HNC) using the US FDA Adverse Event Reporting System (FAERS). The present study aims to evaluate ADE signal characteristics of both agents to inform clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data extracted from FAERS included patient baseline characteristics, which were summarized in a baseline table. Disproportionality analysis with reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) was applied to identify signals at the system organ class (SOC) and preferred term (PT) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For Nivolumab, three significant SOC-level signals were identified\u2014benign\/malignant tumors (including cysts\/polyps), hepatobiliary disorders, and endocrine abnormalities. At the PT level, 58 effective signals were observed, with immune-related events such as thyroid dysfunction being particularly frequent. For Cetuximab, 40 effective PT-level signals were detected, dominated by dermatologic toxicity (rash) and metabolic abnormalities (hypomagnesemia). Comparative analysis revealed marked differences between the two drugs: Nivolumab was more strongly associated with immune-mediated reactions, whereas Cetuximab was characterized by cutaneous and metabolic toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study represents the first FAERS-based assessment of ADE risk differences between Nivolumab and Cetuximab in HNC, offering valuable evidence for clinical monitoring and drug selection. As signal detection reflects statistical correlation rather than causality, confirmatory clinical validation remains necessary. Integration of real-world evidence with prospective clinical trials will be essential to enhance drug safety evaluation systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1658535","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:40:58Z","timestamp":1761720058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S317234","article-title":"The role and mechanism of MALAT1 long non-coding RNA in the diagnosis and treatment of head and neck squamous cell carcinoma","volume":"14","author":"Ye","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2021.06.019","article-title":"Long-term quality of life outcome after spondylodiscitis treatment","volume":"21","author":"Stoop","year":"2021","journal-title":"Spine J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20293","article-title":"Synergistic effect of alcohol drinking and smoking on","volume":"111","author":"Salaspuro","year":"2004","journal-title":"Vivo acetaldehyde concentration saliva. Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17588359241288251","DOI":"10.1177\/17588359241288251","article-title":"Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials","volume":"17","author":"Gurizzan","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604965","article-title":"Prediction of response in head and neck tumor: focus on main hot topics in research","volume":"10","author":"Belgioia","year":"2020","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13541","article-title":"Exacerbation of cancer pain after administering immune checkpoint inhibitor in a patient taking opioids: A case report","volume":"47","author":"Sumimoto","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00262-024-03635-3","article-title":"Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells","volume":"73","author":"Rajasekaran","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41598-022-06084-z","article-title":"Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma","volume":"12","author":"Okamoto","year":"2022","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03265-7","article-title":"Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab","volume":"72","author":"Ikoma","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1758835920975355","DOI":"10.1177\/1758835920975355","article-title":"Comparative efficacy and safety of radiotherapy\/cetuximab versus radiotherapy\/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data","volume":"12","author":"Mei","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00784","DOI":"10.14309\/crj.0000000000000784","article-title":"Cetuximab-induced small intestine stricture in metastatic squamous cell carcinoma of the oral cavity","volume":"9","author":"Eisa","year":"2022","journal-title":"ACG Case Rep J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41598-025-85831-4","article-title":"& Wan, Y. A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1139\/cjpp-2024-0078","article-title":"Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database","volume":"103","author":"Han","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4065\/83.4.489","article-title":"Head and neck cancer: changing epidemiology, diagnosis, and treatment","volume":"83","author":"Marur","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15117","article-title":"Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance","volume":"112","author":"Yamamoto","year":"2021","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10020217","article-title":"Tolerability on serious adverse events of first-line bevacizumab and cetuximab for RAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis","volume":"10","author":"Han","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/genes16030342","article-title":"Genetic diversity and ethnic tapestry of Kazakhstan as inferred from HLA polymorphism and population dynamics: A comprehensive review","volume":"16","author":"Turganbekova","year":"2025","journal-title":"Genes (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1002\/mco2.702","article-title":"Head and neck cancer: pathogenesis and targeted therapy","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1186\/s12885-017-3785-4","article-title":"Serial pseudoprogression of metastatic Malignant melanoma in a patient treated with nivolumab: a case report","volume":"17","author":"Ozaki","year":"2017","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.07.003","article-title":"Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies","volume":"20","author":"Borch","year":"2015","journal-title":"Drug Discov Today"},{"key":"B29","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: A case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.750380","article-title":"Precision medicine in autoimmune thyroiditis and hypothyroidism","volume":"12","author":"Ferrari","year":"2021","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"112967","DOI":"10.1016\/j.ejca.2023.112967","article-title":"Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study","volume":"191","author":"Lumlertgul","year":"2023","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji242","article-title":"Cetuximab therapy and symptomatic hypomagnesemia","volume":"97","author":"Schrag","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16629","article-title":"Cetuximab enhances the efficacy of MRTX1133, a novel KRAS(G12D) inhibitor, in colorectal cancer treatment","volume":"43","author":"Kataoka","year":"2023","journal-title":"Anticancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.25259\/JCIS_194_2021","article-title":"Computed tomography imaging findings of nivolumab-induced thyroid dysfunction","volume":"12","author":"Oki","year":"2022","journal-title":"J Clin Imaging Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40618-020-01297-3","article-title":"Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH","volume":"44","author":"Siddiqui","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23-00714","article-title":"Risk factors of cetuximab-induced hypomagnesemia and the effect of magnesium prophylaxis in patients with head and neck cancer: A retrospective study","volume":"47","author":"Matsukane","year":"2024","journal-title":"Biol Pharm Bull"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10811-3","article-title":"Natalizumab-induced pneumonitis","volume":"269","author":"Kaninia","year":"2022","journal-title":"J Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.clinre.2025.102618","article-title":"Natalizumab-induced autoimmune liver injury","volume":"49","author":"Rodriguez-Martinez","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05862-7","article-title":"Prospective practice survey of management of cetuximab-related skin reactions","volume":"29","author":"Lugtenberg","year":"2021","journal-title":"Support Care Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2020.04.020","article-title":"Severe vernal keratoconjunctivitis complicated by anaesthetic abuse","volume":"55","author":"Anchouche","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/s19122807","article-title":"Assessment of the spatial distribution of moisture content in granular material using electrical impedance tomography","volume":"19","author":"Porzuczek","year":"2019","journal-title":"Sensors (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:40:58Z","timestamp":1761720058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1658535"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658535","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1658535"}}